Form 13-F position report

LIFECORE BIOMEDICAL INC COM

Reported by VANGUARD GROUP INC

LFCR CUSIP 514766104 Manager CIK 0000102909

Reported 1,350,567 shares, down 114,117 (7.8%) from the prior quarter.

Reported value 136.2%; share count -7.8% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2023
Shares 1,350,567 Quarter-end amount reported
Reported value $13,059,983 Fair value at quarter end
Consecutive quarters held 41 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-03-31 17799000
2021-06-30 15728000
2021-09-30 13278000
2021-12-31 13961000
2022-03-31 15401000
2022-06-30 12678000
2022-09-30 11273000
2022-12-31 8254671
2023-03-31 5529182
2023-06-30 13059983
2023-09-30 10190028
2023-12-31 8360009
2024-03-31 6291585
2024-06-30 6617741
2024-09-30 6484014
2024-12-31 11372751
2025-03-31 10888184
2025-06-30 13072535
2025-09-30 11943580
2025-12-31 13690589

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for LIFECORE BIOMEDICAL INC COM held by VANGUARD GROUP INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Added 1,673,666 +50,897 (3.1%) < 0.01% $13,690,589 2026-01-29
Q3 2025 Added 1,622,769 +12,851 (0.8%) < 0.01% $11,943,580 2025-11-07
Q2 2025 Added 1,609,918 +63,301 (4.1%) < 0.01% $13,072,535 2025-08-11
Q1 2025 Added 1,546,617 +15,964 (1.0%) < 0.01% $10,888,184 2025-05-09
Q4 2024 Added 1,530,653 +215,437 (16.4%) < 0.01% $11,372,751 2025-02-11
Q3 2024 Added 1,315,216 +25,208 (2.0%) < 0.01% $6,484,014 2024-11-13
Q2 2024 Added 1,290,008 +105,152 (8.9%) < 0.01% $6,617,741 2024-08-13
Q1 2024 Reduced 1,184,856 -165,711 (-12.3%) < 0.01% $6,291,585 2024-05-10
Q4 2023 Unchanged 1,350,567 0 (0.0%) < 0.01% $8,360,009 2024-02-14
Q3 2023 Unchanged 1,350,567 0 (0.0%) < 0.01% $10,190,028 2023-11-14
Q2 2023 Reduced 1,350,567 -114,117 (-7.8%) < 0.01% $13,059,983 2023-08-14
Q1 2023 Added 1,464,684 +190,815 (15.0%) < 0.01% $5,529,182 2023-05-15
Q4 2022 Added 1,273,869 +5,770 (0.5%) < 0.01% $8,254,671 2023-02-10
Q3 2022 Reduced 1,268,099 -3,488 (-0.3%) < 0.01% $11,273,000 2022-11-14
Q2 2022 Reduced 1,271,587 -58,313 (-4.4%) < 0.01% $12,678,000 2022-08-12
Q1 2022 Added 1,329,900 +72,064 (5.7%) < 0.01% $15,401,000 2022-05-13
Q4 2021 Reduced 1,257,836 -182,219 (-12.7%) < 0.01% $13,961,000 2022-02-14
Q3 2021 Added 1,440,055 +42,060 (3.0%) < 0.01% $13,278,000 2021-11-12
Q2 2021 Reduced 1,397,995 -281,169 (-16.7%) < 0.01% $15,728,000 2021-08-13
Q1 2021 Added 1,679,164 +7,323 (0.4%) < 0.01% $17,799,000 2021-05-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

102 managers reported LIFECORE BIOMEDICAL INC COM for Q2 2023.

Managers reporting LIFECORE BIOMEDICAL INC COM in Q2 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
WYNNEFIELD CAPITAL INC Unchanged 4,923,545 0 23.8% $47,610,680 41 qtrs
Legion Partners Asset Management LLC Unchanged 2,940,340 0 8.31% $28,433,088 16 qtrs
22NW LP Unchanged 1,755,161 0 10.6% $16,972,407 9 qtrs
Cove Street Capital LLC Reduced 1,619,536 -264,808 4.86% $15,660,913 14 qtrs
VANGUARD GROUP INC This report Reduced 1,350,567 -114,117 < 0.01% $13,059,983 41 qtrs
MORGAN STANLEY Reduced 817,494 -51,606 < 0.01% $7,905,167 41 qtrs
BlackRock Inc Reduced 532,043 -1,366,452 < 0.01% $5,144,856 41 qtrs
Visionary Wealth Advisors Reduced 499,309 -960 0.39% $4,828,318 15 qtrs
TOCQUEVILLE ASSET MANAGEMENT L P Reduced 451,700 -93,500 0.08% $4,367,939 17 qtrs
MILLENNIUM MANAGEMENT LLC New 375,622 +375,622 < 0.01% $3,632,265 14 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
August 14, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
0
None
1,350,567

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.